Business context and reporting period
Materialise NV is a Belgium-based additive-manufacturing company operating in Software, Medical and Manufacturing. This Form 20-F covers the fiscal year ended December 31, 2023—not standalone 2023 Q4 results. The filing does not provide a clear standalone Q4 value for the financial metrics below. Financial statements are prepared under IFRS as issued by the IASB.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | €256.1 million | €232.0 million |
| Gross profit / margin | €145.1 million / 56.7% | €128.8 million / 55.5% |
| Operating profit (loss) | €5.6 million | (€2.9 million) |
| Net profit (loss) | €6.7 million | (€2.2 million) |
| Adjusted EBITDA | €31.4 million | €19.0 million |
| Cash flow from operations | €20.2 million | €22.3 million |
| Cash and cash equivalents at year-end | €127.6 million | €140.9 million |
| Loans and borrowings, including lease liabilities | €64.4 million | €81.0 million |
Capital expenditures were €11.8 million, down from €24.8 million in 2022. Cash decreased by €13.2 million during 2023; financing cash outflows were €22.4 million, including €20.3 million of loan and lease repayments. The €50 million KBC delayed-draw facility remained undrawn. Management said it expected sufficient liquidity for the next 12 months.
Revenue by segment
| Segment | FY 2023 revenue | Change vs. FY 2022 | FY 2023 Adjusted EBITDA margin |
|---|---|---|---|
| Software | €44.4 million | +1.7% | 16.8% (2022: 3.5%) |
| Medical | €101.4 million | +19.5% | 26.2% (2022: 22.2%) |
| Manufacturing | €110.3 million | +6.6% | 6.8% (2022: 8.0%) |
One Medical-segment customer accounted for €39.9 million, or approximately 15.6% of 2023 consolidated revenue.
Material changes versus the prior year
- Revenue rose 10.4%, with growth in all three segments; Medical led the increase.
- Gross margin improved by 1.2 percentage points. Operating results returned to profit, and net income improved from a loss to a profit.
- Adjusted EBITDA increased to €31.4 million from €19.0 million. The reported measure is non-IFRS and includes adjustments, including impairments.
- Net other operating income shifted from positive €3.2 million to negative €6.5 million. Drivers included a €5.2 million arbitration settlement and approximately €4.2 million of impairments; grants and tax-related income partly offset these costs.
- Cash from operations declined by 9.6%, while year-end cash fell by €13.3 million. Debt declined by €16.6 million.
Outlook, commentary and risks
- No specific numeric 2024 revenue, profit or EBITDA guidance is provided in the supplied filing text. Management described continued investment in cloud-based software, personalized medical products and certified manufacturing capacity, and identified end-use 3D-printed parts as a growth opportunity.
- Management warned that the shift toward cloud subscriptions may affect near-term software revenue. CO-AM platform adoption, product development and customer migration remain execution risks.
- The war in Ukraine continues to affect the company’s Kyiv operations, which support engineering, software development and IT. Management reported no significant customer-service disruption as of the filing date but said costs, project delays or operational disruption could worsen.
- Inflation increased labor, energy, materials and freight costs; price increases did not fully offset these pressures. Foreign exchange is also a risk; the company had $11.2 million of U.S.-dollar hedges in place at year-end, maturing before the end of 2024.
- Medical products face extensive regulatory and quality-system requirements, including EU and U.S. rules. Other material risks include competition, customer and industry concentration, supplier dependence, cybersecurity and privacy, intellectual property, and integration or returns from investments.
- A May 2023 arbitration decision ordered Materialise to pay Zimmer Biomet €5.0 million plus interest; the company recorded an approximately €5.2 million settlement expense and disclosed that no amount had previously been accrued.
- Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the independent auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Review the full-year IFRS statements and non-IFRS Adjusted EBITDA reconciliation, particularly the impairment and arbitration adjustments.
- Check subsequent quarterly disclosures for 2024 growth, margins, cash generation and progress in recurring software revenue and CO-AM adoption.
- Monitor the concentrated Medical customer relationship and the effect of the Zimmer Biomet arbitration payment.
- Track cash, working capital, scheduled debt repayments, covenant compliance and any draw on the €50 million KBC facility.
- Assess developments affecting Kyiv operations, inflation and foreign exchange, medical-device regulation, and the impaired Materialise Motion and Engimplan businesses.